Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

NCT00648739 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
26
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns.

Conditions

Interventions

Sponsor

Alexion Pharmaceuticals, Inc.